ClinicalTrials.gg
RecruitingNCT02836808CAIPADIUpdated Mar 6, 2018

Validation of an Integrated Attention Model for Patients With Type 2 Diabetes

An interventional study of CAIPaDi in Type 2 Diabetes, sponsored by Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran. Recruiting at 1 site in Mexico. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2018-03-06.

Sponsored by Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Registered 2 years 5 months after the study started (first participant enrolled Oct 2013, registered Apr 2016).
  • Started Oct 2013; still recruiting 13 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
1,200
Allocation
Non-randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 10 studies in Diabetes Mellitus, Type 2 by Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran — 3 open to participants now, 5 under way, none of them phase 3. Diabetes Mellitus, Type 2 · Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran.

Started
2013
the only one that year
No phase
6 of 10
1 open now
Registered
2nd of 10
by date

Among the 10 studies in Diabetes Mellitus, Type 2 by Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, this one is the only one that started in 2013, is one of 6 with no phase, and was the 2nd registered.

Diabetes Mellitus, Type 2

10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

3 of the 10 studies in Diabetes Mellitus, Type 2 by Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 10 studies in Diabetes Mellitus, Type 2 by Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, or all of them as a file.
02

Study summary

Abstract: Empowerment interventions for chronic diseases are an evolving process. No agreement exists regarding the necessary components and methodologies to be applied. Systematic reviews have assessed the effect of self-management interventions. Improvements in illness beliefs, adherence to drug therapy and glucose monitoring have been reported. In the long term, no major changes have been achieved in weight, physical activity, smoking status, and depression scores.

There is a need for additional studies. The Center for Comprehensive Care of Patients with Diabetes (CAIPaDi) program is an intervention designed to provide education and empowerment techniques (using simple low-cost interactive tools) over a short period of time followed by at-distance support using internet or cell phone technology. The target population consists of patients with type 2 diabetes, free of chronic complications who are non-smokers. The intervention is composed of four monthly visits followed by a continuous at-distance support system. At each visit, patients stay for six hours in the center. Information is presented in group sessions. Empowerment techniques are applied during individual exchanges with the team or during facilitated group sessions. In summary, empowerment programs are an unmet need in many healthcare services.

Read the detailed description
  1. Background: There are major deficiencies in the attention quality provided to people with diabetes in Mexico. The percentage of compliance of therapeutic objectives is noticeably lower than the one informed in developed countries. It is required to have structured management strategies, adapted to traits of our population, which allow improving attention quality in the medium term. The National Institute of Medical Sciences and Nutrition Salvador Zubirán (INCMNSZ) developed an integrated management program by using the best evidence available. The target population is people with type 2 diabetes, with less than 5 years with the diagnosis, and is free from chronic complications. Selection criteria allow the intervention benefit to diminish incidence of chronic complications.
  2. Hypothesis: "The management strategy applied at the Center of Comprehensive Care for the Patient with Diabetes (CAIPaDi) allows achieving the international treatment standards (proposed by NCQA) in a two-year period".
  3. General and Specific objectives:

    General objective: To quantify the results one year after starting the integrated management program oriented to self-care activities applied at CAIPaDi.

    Specific objectives:

    • To measure the program impact (after 4 months, one and two years) based on the following variables: self-care (measured with standardized questionnaires), efficacy parameters (HbA1c, fasting glycemia, blood lipids, arterial pressure and use of anti-platelet aggregates), execution parameters (compliance of evaluations and preventive measures such as the search for microalbuminuria, ophthalmologic check, influenza vaccination, among others), incidence of micro- and macrovascular complications of diabetes, hospitalizations, use of emergency service or unforeseen expenses related to diabetes.
    • To compare the efficacy and execution parameters of the cases attended at the center, with patients with similar characteristics attended at the "Internal Medicine" service of the INCMNSZ.
    • To carry out a study of the social-economic impact of the intervention.
  4. Goals: It is intended to validate an intervention that provides integrated attention to people with diabetes, in order to generate in the patient and his/her family, the competencies required for self-care in the long term and the prevention of chronic characteristics. Intervention is low-cost. This characteristic, along with the intervention systematization will allow the model to be exportable to the first-contact units.
  5. Scientific Methodology: CAIPaDi has the mission of improving quality of life of patients with diabetes by means of an intervention adapted to the needs of patients, applying step-by-step action programs".

    Intervention consists of four monthly visits, each one being 6 hours long. The visits have individual and group sessions. The nine specialists in the multidisciplinary team are endocrinologists, diabetes educator, nutritionists, psychologist, dentists, psychiatrist, specialist in physical activity, ophthalmologist and foot care. Some of the functions may be fulfilled by the same health professional, previously trained.

    At each session, standardized actions are applied, which are assessed with preset indicators. At the initial and at yearly visits the following laboratory tests are taken: glycated hemoglobin, blood chemistry, lipid profile, liver function tests, albumin-creatinine index in an isolated urine sample, and 12-deviation electrocardiogram. At the yearly visits the patients receive reinforcement and treatment modifications as needed.

    Contact is kept with patients via phone calls, e-mails and messages on the mobile phone. Patients are asked to send their assessments on preset dates. Materials and tools are developed, which allow measuring information from the study in real time, empowerment of patients and decision-making by the multi-disciplinary team, based on clinical practice guidelines.

    There will be information from 1200 patients with 2-year follow-up. Besides having information from 1200 additional cases with follow-up at one year, and other 1200 others with assessments at 6 months. Therefore, the population for assessing execution variables shall be of 3600 participants. Such sample size allows us to detect differences higher than 5% in the percentage of cases that comply with the therapeutic objectives by comparing them with the initial assessment. As a secondary analysis, results will be compared with the population that receives attention the "Internal Medicine" service in the INCMNSZ (n=300 subjects).

    Patients will be referred from clinics or first contact physicians outside the Institute.

  6. Expected impacts at medium and long term: This proposal allows validating the intervention designed and applied at CAIPaDi. In case of demonstrating its usefulness and cost-effectiveness, intervention will be exported to first-contact units. Manuals and tools have been developed which will allow the implementation of the program with minimum resources. Such action will allow creating a network of health units that operate with the same quality standards as INCMNSZ.
  7. Infrastructure available at the participating institutions: The INCMNSZ has an area where the center operates.
  8. Deliverable results: Procedure manuals for each of the actions included in the intervention, tools for decision making based on clinical practice guidelines which will be patented, educational materials designed for empowering patients (patentable products), an internet portal, an electronic file, a database, articles in high impact magazines, diploma courses for generating specific competencies related to diabetes treatment and to the center management.
03

Conditions studied

  • Type 2 Diabetes

Keywords

  • Multidisciplinary interventions
  • Long term control
  • Empowerment
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • being over 18 and under 70 years old
  • having diagnosis of type 2 diabetes in the five previous years,
  • having family support
  • free of disabling diabetes complications

Exclusion criteria

Exclusion Criteria:

  • advanced complications of diabetes, such as ischemic heart disease, heart failure III-IV, KDOQI ≥3 renal failure, amputations, cerebral vascular disease, gastroparesis and muscular atrophy .
  • type 1 diabetes mellitus, gestational diabetes or some variant of diabetes related to genetic syndromes, hyperlabile diabetes
  • co-morbidities that limit their such as malignant tumors
  • advanced cognitive impairment or serious psychiatric disorders
  • smoking, alcoholism or illegal drug dependence
  • conditions that require surgical treatment in the short run or which prevent moderated activity.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
1,200 participants (estimated)

Study arms

  • No intervention
    Control

    Patients attended with the standard model of care for diabetes, as out-patients in the Internal Medicine area

  • Experimental
    CAIPaDi

    Patients attended in the Center of Comprehensive Care for the Patient with Diabetes, where they receive attention from 9 specialists in 1 day

    Behavioral: CAIPaDi

Interventions

  • BehavioralCAIPaDi

    Patients are attended in 1 day by 9 specialists (endocrinologist, diabetes educators, nutritionist, psychologist, dentists, psychiatrist, physical activity specialist, foot care and ophthalmologist). They are attended in 4 monthly visits. After the initial phase, patients come back to the Center at 1 and 2 years for evaluation and reinforcement.

06

What researchers measure

Primary outcomes

  1. Diabetes control after 4 visits in a structured multidisciplinary program for patients with diabetes

    HbA1c is measured in percentage (%). HbA1c will be compared from the first visit with the fourth visit.

    Time frame: 3 months

Secondary outcomes

  1. Diabetes control after 1 year in a structured multidisciplinary program for patients with diabetes

    HbA1c is measured in percentage (%). HbA1c will be compared from the fourth visit with the visit 1 year apart.

    Time frame: 1 year

  2. Metabolic parameters are lipid profile after 1 year in a structured multidisciplinary program for patients with diabetes

    Metabolic parameters are lipid profile (cholesterol, HDL cholesterol LDL cholesterol and triglycerides) in mg/dl. All of them will be compared from the fourth visit with the visit 1 year apart.

    Time frame: 1 year

  3. Renal function after 1 year in a structured multidisciplinary program for patients with diabetes

    Renal function in mg/g (albumin/creatinine ratio). Renal function will be compared from the fourth visit with the visit 1 year apart.

    Time frame: 1 year

  4. Self-care by SDSCA questionnaire after 1 year in a structured multidisciplinary program for patients with diabetes

    Self-care evaluation will be determined by SDSCA questionnaire and an objective examination of the patient doing the activities. This will be compared from the fourth visit with the visit 1 year apart.

    Time frame: 1 year

  5. Diabetic complications are eye, renal and foot evaluations after 1 year in a structured multidisciplinary program for patients with diabetes

    Diabetic complications are eye, renal and foot evaluations. All of them will be compared from the fourth visit with the visit 1 year apart.

    Time frame: 1 year

  6. Quality of life after 1 year in a structured multidisciplinary program for patients with diabetes

    Quality of life will be assessed with the DQoL (Diabetes Quality of Life) questionnaire. This will be compared from the fourth visit with the visit 1 year apart.

    Time frame: 1 year

  7. Diabetes control after 2 years in a structured multidisciplinary program for patients with diabetes

    HbA1c is measured in percentage (%). HbA1c to be compared will be from fourth visit, 1 and 2 years apart.

    Time frame: 2 years

  8. Metabolic parameters are lipid profile after 2 years in a structured multidisciplinary program for patients with diabetes

    Metabolic parameters are lipid profile (cholesterol, HDL cholesterol LDL cholesterol and triglycerides) in mg/dl. The parameters to be compared will be from fourth visit, 1 and 2 years apart.

    Time frame: 2 years

  9. Renal function after 2 years in a structured multidisciplinary program for patients with diabetes

    Renal function in mg/g (albumin/creatinine ratio). The parameters to be compared will be from fourth visit, 1 and 2 years apart.

    Time frame: 2 years

  10. Self-care by SDSCA questionnaire after 2 years in a structured multidisciplinary program for patients with diabetes

    Self-care evaluation will be determined by SDSCA questionnaire and an objective examination of the patient doing the activities. The parameters to be compared will be from fourth visit, 1 and 2 years apart.

    Time frame: 2 years

  11. Diabetic complications are eye, renal and foot after 2 years in a structured multidisciplinary program for patients with diabetes

    Diabetic complications are eye, renal and foot evaluations. All of them will be compared from the fourth visit with the visit 1 year apart. The parameters to be compared will be from fourth visit, 1 and 2 years apart.

    Time frame: 2 years

  12. Quality of life after 2 years in a structured multidisciplinary program for patients with diabetes

    Quality of life will be assessed with the DQoL (Diabetes Quality of Life) questionnaire. The parameters to be compared will be from fourth visit, 1 and 2 years apart.

    Time frame: 2 years

  13. Metabolic parameters are lipid profile after 4 visits in a structured multidisciplinary program for patients with diabetes

    Metabolic parameters are lipid profile (cholesterol, HDL cholesterol LDL cholesterol and triglycerides) in mg/dl. All of them will be compared from the first visit with the fourth visit.

    Time frame: 3 months

  14. Renal function after 4 visits in a structured multidisciplinary program for patients with diabetes

    Renal function in mg/g (albumin/creatinine ratio). Renal function will be compared from the first visit with the fourth visit.

    Time frame: 3 months

  15. Self-care by SDSCA questionnaire after 4 visits in a structured multidisciplinary program for patients with diabetes

    Self-care evaluation will be determined by SDSCA questionnaire and an objective.

    Time frame: 3 months

  16. Diabetic complications are eye, renal and foot evaluations after 4 visits in a structured multidisciplinary program for patients with diabetes

    Diabetic complications are eye, renal and foot evaluations. All of them will be compared from the first visit with the fourth visit.

    Time frame: 3 months

  17. Quality of life after 4 visits in a structured multidisciplinary program for patients with diabetes

    Quality of life will be assessed with the DQoL (Diabetes Quality of Life) questionnaire. This will be compared from the first visit with the fourth visit.

    Time frame: 3 months

Other outcomes

  1. Glucose control of the cases attended at the Center compared with those of patients with similar characteristics attended in the "Internal Medicine" service of the INCMNSZ.

    HbA1c is measured in percentage (%). Comparison will be with patients from the Internal Medicine ward, who meet the same clinical characteristics as the patients from the Center.

    Time frame: 2 years

  2. Lipid parameters of the cases attended at the Center compared with those of patients with similar characteristics attended in the "Internal Medicine" service of the INCMNSZ.

    Metabolic parameters are lipid profile (cholesterol, HDL cholesterol LDL cholesterol and triglycerides) in mg/dl. Comparison will be with patients from the Internal Medicine ward, who meet the same clinical characteristics as the patients from the Center.

    Time frame: 2 years

  3. Renal function evaluation of the cases attended at the Center compared with those of patients with similar characteristics attended in the "Internal Medicine" service of the INCMNSZ.

    Renal function in mg/g (albumin/creatinine ratio). Comparison will be with patients from the Internal Medicine ward, who meet the same clinical characteristics as the patients from the Center.

    Time frame: 2 years

  4. Self-care evaluation of the cases attended at the Center compared with those of patients with similar characteristics attended in the "Internal Medicine" service of the INCMNSZ.

    Self-care evaluation will be determined by SDSCA questionnaire and an objective examination of the patient doing the activities. Comparison will be with patients from the Internal Medicine ward, who meet the same clinical characteristics as the patients from the Center.

    Time frame: 2 years

  5. Evaluation of complications of the cases attended at the Center compared with those of patients with similar characteristics attended in the "Internal Medicine" service of the INCMNSZ.

    Diabetic complications are eye, renal and foot evaluations. Comparison will be with patients from the Internal Medicine ward, who meet the same clinical characteristics as the patients from the Center.

    Time frame: 2 years

  6. Quality of life of the cases attended at the Center compared with those of patients with similar characteristics attended in the "Internal Medicine" service of the INCMNSZ.

    Quality of life will be assessed with the DQoL (Diabetes Quality of Life) questionnaire. Comparison will be with patients from the Internal Medicine ward, who meet the same clinical characteristics as the patients from the Center.

    Time frame: 2 years

  7. Social-economic impact of expenses on food of a multidisciplinary intervention for patients with diabetes

    Patients will be asked about expenses on food. It will be included an evaluation of visits to emergency service related to diabetes complications and costs generated from this visit.

    Time frame: 2 years

  8. Social-economic impact of exercising facilities and usage of a multidisciplinary intervention for patients with diabetes

    Patients will be asked about the expense for the use of facilities for exercise at the beginning and at the fourth visit.

    Time frame: 2 years

  9. Social-economic impact of drug treatment of a multidisciplinary intervention for patients with diabetes

    Patients will be asked about the expense drug treatment at the beginning and at the fourth visit. It will be included an evaluation of visits to emergency service related to diabetes complications and costs generated from this visit.

    Time frame: 2 years

  10. Social-economic impact of transportation of a multidisciplinary intervention for patients with diabetes

    Patients will be asked about the expense transportation at the beginning and at the fourth visit. It will be included an evaluation of visits to emergency service related to diabetes complications and costs generated from this visit.

    Time frame: 2 years

  11. Social-economic impact of living and eating expenses of a multidisciplinary intervention for patients with diabetes

    Patients will be asked about the expense living and eating at the beginning and at the fourth visit. It will be included an evaluation of visits to emergency service related to diabetes complications and costs generated from this visit.

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
  • Instituto Nacional de Ciencias Medicas y Nutricion
    Mexico City, DF 14000, Mexico
    Recruiting
    • Carlos A Aguilar-Salinas, MD · Contactcaguilarsalinas@yahoo.com · 52-55-56554523
    • Sergio Hernández, MD · Principal investigator
08

References and documents

Publications

  • Villalpando S, Shamah-Levy T, Rojas R, Aguilar-Salinas CA. Trends for type 2 diabetes and other cardiovascular risk factors in Mexico from 1993-2006. Salud Publica Mex. 2010;52 Suppl 1:S72-9. doi: 10.1590/s0036-36342010000700011. PubMed 20585732 ↗
  • Aguilar Salinas CA, Gómez Diaz RA, Gomez Perez FJ. Diabetes en Mexico: Principales retos y posibles soluciones. Revista ALAD 2011: 19:146-161
  • Tricco AC, Ivers NM, Grimshaw JM, Moher D, Turner L, Galipeau J, Halperin I, Vachon B, Ramsay T, Manns B, Tonelli M, Shojania K. Effectiveness of quality improvement strategies on the management of diabetes: a systematic review and meta-analysis. Lancet. 2012 Jun 16;379(9833):2252-61. doi: 10.1016/S0140-6736(12)60480-2. Epub 2012 Jun 9. PubMed 22683130 ↗
  • Planas LG, Crosby KM, Farmer KC, Harrison DL. Evaluation of a diabetes management program using selected HEDIS measures. J Am Pharm Assoc (2003). 2012;52(6):e130-8. doi: 10.1331/JAPhA.2012.11148. PubMed 23224336 ↗
  • Hernandez-Jimenez S, Garcia-Ulloa C, Mehta R, Aguilar-Salinas CA, Kershenobich-Stalnikowitz D. Innovative models for the empowerment of patients with type 2 diabetes: the CAIPaDi program. Recent Pat Endocr Metab Immune Drug Discov. 2014;8(3):202-9. doi: 10.2174/1872214808999141110155515. PubMed 25381833 ↗
  • Garcia-Ulloa AC, Lechuga-Fonseca C, Del Razo-Olvera FM, Aguilar-Salinas CA, Galaviz KI, Narayan KMV, Hernandez-Jimenez S; Group of Study CAIPaDi. Clinician prescription of lipid-lowering drugs and achievement of treatment goals in patients with newly diagnosed type 2 diabetes mellitus. BMJ Open Diabetes Res Care. 2021 Feb;9(1):e001891. doi: 10.1136/bmjdrc-2020-001891. PubMed 33568360 ↗

Individual participant data

Plan to share: Yes — Journal publication. The information to be shared will be metabolic parameters and questionaire results. The data will be available on 2016. Metabolic parameters will be obtained from blood samples and the questionnaires results from those self-applied or applied during praxis.

Supporting information: Study protocol, Informed consent form, Clinical study report, Analytic code

Time frame: January 2018. The data will be available for 5 years

Access criteria: Undefined

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Oct 2013 to primary completion in Feb 2018, 51 months.

Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 51 months is above that.

Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2016
First posted
Jul 19, 2016
StartActual
Oct 31, 2013
Primary completionActual
Feb 9, 2018
CompletionEst.
Dec 31, 2028
Last update
Mar 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02836808
Responsible party
Sponsor
First posted
Jul 19, 2016
Start date
Oct 31, 2013
Primary completion
Feb 9, 2018
Completion
Dec 31, 2028 (estimated)
Last update
Mar 6, 2018

Study contacts

Sergio Hernández, MD
Contact
sergiohdzj@hotmail.com
57870900 ext. 5045
Carlos A Aguilar-Salinas, MD
Contact
caguilarsalinas@yahoo.com
57870900 ext. 2405
Sergio C Hernández, MD
principal investigator · National Institute of Medical Sciences and Nutrition Salvador Zubirán

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion